HOME ABOUT RRSEARCH GROUPS PUBLICATIONS EDUCATION DOWNLOAD 中文版
  Location: Home > AMHD > Publications
BDNF Val66Met polymorphism and bipolar disorder in European populations: A risk association in case-control, family-based and GWAS studies
2017-09-18 | Author: | From:
BDNF Val66Met polymorphism and bipolar disorder in European populations: A risk association in case-control, family-based and GWAS studies. NeurosciBiobehav Rev, 2016, 68: 218-33

Title: BDNF Val66Met polymorphism and bipolar disorder in European populations: A risk association in case-control, family-based and GWAS studies.

Author: Li M, Chang H, Xiao X

Publication Name: NeurosciBiobehav Rev 

Pub Year: 2016

Volume: 68

Issue:

Page Number: 218-33

IF: 8.580

Abstract:

Brain-derived neurotrophic factor (BDNF) is a nerve growth factor that has antidepressant-like effects in animal models and may be implicated in the etiology of mood-related phenotypes. A functional polymorphism (Val66Met) in the BDNF gene was demonstrated to influence BDNF's secretion and function, as well as mood and cognitive related phenotypes. However, previous genetic associationstudies of Val66Met polymorphism in the clinical risk of mood disorders have been complicated, possibly due to phenotypic diversity, underpowered statistical association or ancestry-specific effects. Here, we collected mood phenotypic and genetic data in over 90,000 individuals from diverse ethnic groups and conducted a systematic meta-analysis. The results showed that the Val66Metpolymorphism was significantly associated with BPD in Europeans (Pmeta=0.0029, OR=1.136), but not in Asians (Pmeta=0.443). Also, it appears that the risk for MDD conferred by BDNF is waning, as the Val66Met variant was not associated with MDD in eitherEuropean or Asian samples (Pmeta>0.5). 

Adress:No.32 Jiaochang Donglu Kunming 650223 Yunnan, China Tel:86-871-65197869